IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported Q2 2017 earnings this Morning, coming in at $0.87 per share, beating Wall Street’s estimates of $0.85 per Share. Revenue for the quarter came in at $508.90 million beating analyst estimates of $502.44 million

Analyst Coverage For IDEXX Laboratories, Inc. (NASDAQ:IDXX)
These are 2 Sell Ratings, 2 Hold Ratings, 3 Buy Ratings .
The current consensus rating for IDEXX Laboratories, Inc. (NASDAQ:IDXX) is Hold (Score: 2.14) with a consensus target price of $170.75 , a potential (2.58% upside)

Recent Insider Trading for IDEXX Laboratories, Inc. (NASDAQ:IDXX)

• On 5/31/2017 Giovani Twigge, Insider, sold 2,572 with an average share price of $166.90 per share and the total transaction amounting to $429,266.80.
• On 5/30/2017 Jonathan W Ayers, Chairman, sold 13,000 with an average share price of $167.82 per share and the total transaction amounting to $2,181,660.00.
• On 5/22/2017 William T End, Director, sold 5,000 with an average share price of $162.55 per share and the total transaction amounting to $812,750.00.
• On 5/10/2017 Jonathan W Ayers, Chairman, sold 27,000 with an average share price of $162.69 per share and the total transaction amounting to $4,392,630.00.
• On 5/5/2017 Jonathan W. Ayers, Chairman, sold 26,000 with an average share price of $160.61 per share and the total transaction amounting to $4,175,860.00.
• On 5/4/2017 Rebecca M Henderson, Director, sold 1,700 with an average share price of $159.95 per share and the total transaction amounting to $271,915.00.

Recent Trading for IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Shares of IDEXX Laboratories, Inc. closed the previous trading session at 157.70 down -8.76 -5.26% with 578,514 shares trading hands.